Mortality Up for Some Cancers in Urban-Dwelling Native Americans

Share this content:
Mortality Up for Some Cancers in Urban-Dwelling Native Americans
Mortality Up for Some Cancers in Urban-Dwelling Native Americans

THURSDAY, Nov. 30, 2017 (HealthDay News) -- Urban American Indians and Alaskan Natives (AIAN) with cancer have a significantly higher comorbidity burden, and have higher mortality for some cancers, according to a study published online Nov. 29 in Cancer Research.

Marc A. Emerson, M.P.H., from the National Cancer Institute in Bethesda, Md., and colleagues compared all-cause and prostate, breast, lung, and colorectal cancer-specific mortality among 582 AIAN and 82,696 non-Hispanic white (NHW) individuals diagnosed with primary invasive breast, prostate, lung, or colorectal cancer. Data were extracted on sociodemographic, comorbidity, tumor, clinical, and treatment characteristics.

The researchers found that the comorbidity burden was significantly higher for AIAN than NHW (P < 0.05). All-cause mortality and cancer-specific mortality were significantly higher for AIAN than NHW patients with breast or prostate cancer (hazard ratios, 1.47 and 1.87, respectively), but not those with lung or colorectal cancer, after adjustment for patient, disease characteristics, and Charlson comorbidity scores. Mortality was higher for AIAN than NHW with some cancers despite almost equal access to preventive services and cancer care in this setting; furthermore, a greater proportion of AIAN cancer patients had multiple comorbid conditions.

"This study provides severely needed information on the cancer experience of the 71 percent of AIANs who live in urban areas and access cancer care outside of the Indian Health Services, from which the vast majority of AIAN cancer information comes," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »